The Role of Histamine in the Pathophysiology of Asthma and the Clinical Efficacy of Antihistamines in Asthma Therapy
1
Division of Respirology, Department of Internal Medicine, Takizawa Central Hospital, Takizawa 020-0664, Japan
2
Division of Bioregulatory Pharmacology, Department of Pharmacology, Iwate Medical University, Morioka 028-3694, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(7), 1733; https://doi.org/10.3390/ijms20071733
Received: 3 February 2019 / Revised: 30 March 2019 / Accepted: 1 April 2019 / Published: 8 April 2019
(This article belongs to the Special Issue Histamine-Related Molecules as Therapeutic Targets)
Mast cells play a critical role in the pathogenesis of allergic asthma. Histamine is a central mediator released from mast cells through allergic reactions. Histamine plays a role in airway obstruction via smooth muscle contraction, bronchial secretion, and airway mucosal edema. However, previous clinical trials of H1 receptor antagonists (H1RAs) as a treatment for asthma were not successful. In recent years, type 2 innate immunity has been demonstrated to be involved in allergic airway inflammation. Allergic asthma is defined by IgE antibody-mediated mast cell degranulation, while group 2 innate lymphoid cells (ILC2) induce eosinophilic inflammation in nonallergic asthma without allergen-specific IgE. Anti-IgE therapy has demonstrated prominent efficacy in the treatment of severe allergic asthmatics sensitized with specific perennial allergens. Furthermore, recent trials of specific cytokine antagonists indicated that these antagonists were effective in only some subtypes of asthma. Accordingly, H1RAs may show significant clinical efficacy for some subtypes of allergic asthma in which histamine is deeply associated with the pathophysiology.
View Full-Text
Keywords:
airway obstruction; histamine receptor; histamine receptor 1 antagonist; histamine transporter; OCT-3; Th2 cell; allergen; IgE; innate immunity; type 2 innate lymphoid cells; allergic rhinitis
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Yamauchi, K.; Ogasawara, M. The Role of Histamine in the Pathophysiology of Asthma and the Clinical Efficacy of Antihistamines in Asthma Therapy. Int. J. Mol. Sci. 2019, 20, 1733.
AMA Style
Yamauchi K, Ogasawara M. The Role of Histamine in the Pathophysiology of Asthma and the Clinical Efficacy of Antihistamines in Asthma Therapy. International Journal of Molecular Sciences. 2019; 20(7):1733.
Chicago/Turabian StyleYamauchi, Kohei; Ogasawara, Masahito. 2019. "The Role of Histamine in the Pathophysiology of Asthma and the Clinical Efficacy of Antihistamines in Asthma Therapy" Int. J. Mol. Sci. 20, no. 7: 1733.
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit
